Oxidative stress in methamphetamine-induced self-injurious behavior in mice.
Previous studies have shown that N-methyl-D-aspartate, the formation of free radicals and poly(ADP-ribose) polymerase are related to methamphetamine-induced neurotoxicity. This study was designed to investigate the involvement of oxidative stress in methamphetamine-induced self-injurious behavior in mice. In this study, methamphetamine (20 mg/kg) induced continuous self-injurious behavior in six of seven mice. N-methyl-D-aspartate-receptor antagonists (MK801 and 3-((R)-2-carboxypiperazin-4-yl) propyl-1-phosphonic acid) significantly attenuated this methamphetamine-induced self-injurious behavior. These results suggest that the activation of N-methyl-D-aspartate receptors is involved in methamphetamine-induced self-injurious behavior. Furthermore, we found that the nonselective nitric oxide synthase inhibitor l-N-nitro-L-arginine methyl ester hydrochloride and the neuronal nitric oxide synthase inhibitor 7-nitroindazole, but not the inducible nitric oxide synthase inhibitor aminoguanidine, the free-radical inhibitors fullerene and 3-methyl-1-phenyl-2-pyrazolin-5-one-186, or the poly(ADP-ribose) polymerase inhibitor benzamide, significantly attenuated methamphetamine-induced self-injurious behavior. The present results show that oxidative stress, which is mediated by the activation of neuronal nitric oxide synthase, is associated with methamphetamine-induced self-injurious behavior. These findings may help us to better understand the clinical phenomenon of self-injurious behavior.
Mori
Tomohisa
T
Department of Legal Medicine, Tokyo Women's Medical University, Tokyo, Japan.
Ito
Shinobu
S
Kita
Taizo
T
Narita
Minoru
M
Suzuki
Tsutomu
T
Matsubayashi
Kenji
K
Sawaguchi
Toshiko
T
D000818:Animals; D001549:Benzamides / Q000494:pharmacology; D001679:Biogenic Amines / Q000378:metabolism; D001923:Brain Chemistry / Q000187:drug effects; D002452:Cell Count; D000697:Central Nervous System Stimulants / Q000008:administration & dosage / Q000633:toxicity*; D016291:Dizocilpine Maleate / Q000494:pharmacology; D004298:Dopamine / Q000378:metabolism; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D007150:Immunohistochemistry; D008297:Male; D008694:Methamphetamine / Q000008:administration & dosage / Q000633:toxicity*; D051379:Mice; D008845:Microinjections; D009043:Motor Activity / Q000187:drug effects; D017072:Neostriatum; D018384:Oxidative Stress / Q000502:physiology*; D010879:Piperazines / Q000494:pharmacology; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D016728:Self-Injurious Behavior / Q000139:chemically induced* / Q000378:metabolism* / Q000523:psychology
D001549:Benzamides; D001679:Biogenic Amines; D000697:Central Nervous System Stimulants; D018691:Excitatory Amino Acid Antagonists; D010879:Piperazines; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D008694:Methamphetamine; D016291:Dizocilpine Maleate; C037689:benzamide; C050592:3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid; D004298:Dopamine